| T O P I C R E V I E W |
| ebehre |
High through put screening (HTS) is not the bottle neck in drug discovery, rather deciding which hit is the best lead to optimize and take into clinical trials is the most critical. The Biacore S51 is a new automated biosensor specifically optimized for direct binding assays with small molecules in non-aqueous buffers (e.g. DMSO). This platform is ideal for hit confirmation, characterization and lead optimization including secondary screening (specificity, relative ranking), compound characterization (affinity, kinetics), early ADME (lipid and serum protein binding), and kinetic based QSAR analysis. Unpromising hits can be identified and discarded earlier in the drug discovery process, saving millions of dollars in development costs. Compounds taken to clinical trials have a higher chance of success. For more information see this link http://www.biacore.com/products/systemsandsoftware/s51/bcs51.lasso?goback=1, or contact Evan Behre, Sales Account Scientist, Biacore, Inc. [email protected] Edited by - ebehre on 09/25/2002 14:29:34 |
|
